Atreca suspends solid tumor antibody development, cuts headcount by 40%

In a bid to extend its cash runway, Atreca has suspended the clinical development of its solid tumor monoclonal antibody ATRC-101, slashing staff numbers by 40%. The company will focus on its preclinical antibody-drug conjugate (ADC) assets instead.

The San Carlos, CA biotech’s Phase Ib ATRC-101…
Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks